This article is available online at http://www.jlr.org environment of early endosomes and the LDLR recycles to the cell surface. Lipoprotein release and LDLR recycling are facilitated by a pH-dependent open (ligand-active) to closed (ligand-inactive) conformational switch involving an intramolecular interaction between the R4/R5 repeats of the ligand-binding domain and a ␤ -propeller region in the epidermal growth factor (EGF) precursor homology domain of LDLR ( 2, 3 ). LDLR-mediated uptake of LDL in the liver is the primary means of plasma LDL clearance and thus infl uences steady-state plasma LDL-cholesterol (LDL-C) levels and associated risk of coronary artery disease ( 4 ).
Southwestern Medical Center, Dallas, TX); C7 antibody was purifi ed from conditioned medium of mouse hybridoma cells (ATCC, CRL-1691) by protein A affi nity chromatography using Profi nia TM affi nity chromatography purifi cation system (Bio-Rad); mouse anti-human transferrin receptor antibody was purchased from Life Technologies; monoclonal anti-FLAG M2 antibody were from Sigma-Aldrich. Secondary IRDye-labeled goat anti-mouse and anti-rabbit IgG antibodies were from LI-COR Biosciences.
Protein purifi cation and labeling
FLAG epitope-tagged recombinant human wild-type PCSK9 and PCSK9-D374Y were purifi ed as previously described ( 39 ) . PCSK9 was labeled with the AlexaFluor488 Protein Labeling Kit (Life Technologies) as per manufacturer's protocol followed by gel fi ltration chromatography on a Superdex 200 10/300 GL column (GE Healthcare) to remove unbound dye. PCSK9 was labeled with EZ-Link TM Sulfo-NHS-SS-Biotin (Thermo Scientifi c Pierce) according to the manufacturer's protocol. Free biotin was quenched in Tris-glycine buffer (25 mM Tris-HCl, pH 7.4; 192 mM Glycine) and removed from biotinylated PCSK9 by gel fi ltration.
Radiolabeling of proteins
Purifi ed wild-type PCSK9, PCSK9-D374Y or C7 monoclonal antibody [400 µg in 200 µl Hepes-buffered saline containing 2 mM CaCl 2 , pH 7.4 (HBS-C)] were incubated with carrier-free Na 125 I (2 mCi) in Precoated Iodination Tubes (Thermo Scientifi c Pierce) for 10 min. The reaction was stopped by removal to a glass test tube and brought to a 500 µl volume in scavenging buffer (HBS-C containing 1 mM NaI carrier and 2 mg/ml tyrosine) and incubated 5 min. Free 125 I and scavenged 125 I were removed from iodinated proteins by gel fi ltration on a PD10 column (GE Healthcare) equilibrated in HBS-C. Integrity of iodinated proteins was confi rmed by SDS-PAGE and autoradiography of dried gels. Radiolabeled proteins were stored at 4°C and used within two weeks.
Cultured cell experiments
SV-589 human skin fi broblast cells (kindly provided by J. Goldstein, University of Texas Southwestern Medical Center, Dallas, TX) and HepG2 human hepatoma cells (ATCC, HB-8065) were maintained in monolayer culture at 37°C and 5% CO 2 (SV-589) or 8.8% CO 2 (HepG2). The base medium was DMEM (Gibco-Life Technologies) containing 4.5 g/L glucose for SV-589 cells or DMEM containing 1 g/L glucose for HepG2 cells. Medium A contained DMEM supplemented 100 U/ml penicillin and 100 µg/ml streptomycin sulfate; Medium B contained Medium A supplemented with 10% FBS (v/v); sterol-depleting Medium C contained Medium A supplemented with 5% (v/v) NCLPDS, 10 µM pravastatin, and 50 µM sodium mevalonate; sterol-supplemented Medium D contained Medium A with 5% (v/v) NCLPDS, 10 µg/ml cholesterol, and 1 µg/ml 25-hydroxycholesterol. Cells were plated and grown in Medium B to approximately 60% confl uency prior to start of experiments.
Cell surface biotinylation and immunoblotting
SV-589 and HepG2 cells were cultured overnight in steroldepleting or sterol-supplemented media conditions prior to treatment with PCSK9 (see fi gure legends for details). Following treatments, cells were scraped and collected in PBS and wholecell extracts were prepared in Tris lysis buffer [50 mM Tris-Cl, pH 7.4; 150 mM NaCl; 1% Nonidet P-40 (EMD Biosciences); 0.5% sodium deoxycholate; 5 mM EDTA; 5 mM EGTA; Complete TM protease inhibitor cocktail; 1 mM phenylmethylsulfonyl fl uoride (PMSF)]. For some experiments, cell surface proteins were monoclonal antibodies that disrupt binding to LDLR resulted in substantial LDL-C lowering in Phase II clinical trials (22) (23) (24) , supporting that secreted PCSK9 is a main regulator of circulating LDL-C levels in humans.
PCSK9 is primarily expressed and secreted from liver, with lower levels of expression in kidney, intestine and brain ( 25 ) . PCSK9 is initially synthesized as a soluble 74 kDa precursor that undergoes autocatalytic cleavage in the ER lumen, releasing an approximately 14 kDa prodomain segment, which noncovalently associates with the approximately 60 kDa catalytic/C-terminal domains of PCSK9 and acts as a folding chaperone and inhibitor of inherent protease activity ( 8 ) . The prodomain remains tightly bound within the catalytic pocket and as a consequence mature secreted PCSK9 is catalytically inert ( 12, 13 ) . Catalytic activity is not required for PCSK9 to direct LDLR degradation in hepatic cells in culture or in mouse liver ( 26, 27 ) . While the precise mechanism remains undefi ned, it is theorized that PCSK9 binding to the EGF-A domain inhibits the acid-dependent open-to-closed conformational switch of the LDLR in early endosomes, making the receptor more prone to lysosomal sorting mechanisms or proteolytic attack (28) (29) (30) . In addition to the established binding interface between the PCSK9 catalytic domain and LDLR EGF-A domain, deletion mutagenesis and cellular LDLR degradation studies have revealed requirements for the C-terminal domain of PCSK9 and at least three LDLR ligand binding repeats, suggesting the involvement of these domain regions in structural aspects of LDLR degradation or additional protein-protein interactions ( 28, (31) (32) (33) (34) .
Although highly active in liver-derived cells in culture, exogenous PCSK9 is much less potent at directing LDLR degradation in immortalized fi broblasts, despite internalization along with LDLRs into endosomal compartments ( 5, 35 ) . To explore mechanisms of intracellular PCSK9 resistance, we examined LDLR-dependent uptake and traffi cking of PCSK9 in SV-589 cells, a line of SV40-transformed human skin fi broblasts shown to be highly resistant to PCSK9-mediated LDLR degradation ( 35 ) .
MATERIALS AND METHODS

Materials
We obtained fetal bovine serum (FBS), newborn calf serum, human transferrin and Lipofectamine 2000 from Life Technologies. E64 (N-[N-(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucyl] agmatine) and EDTA-free Complete TM Protease Inhibitor Tablets were obtained from Roche. PureProteome TM Streptavidin Magnetic Beads from Millipore. IRDye800CW Streptavidin was from LI-COR Biosciences. Na 125 I was from PerkinElmer. Cholesterol and 25-hydroxycholesterol were purchased from Steroloids, and all other chemicals and reagents from Sigma unless otherwise specifi ed. LDLR cDNA expression vector was pLDLR17 ( 36 ) . Sodium mevalonate was prepared from mevalonic acid as described ( 37 ) . Newborn calf lipoprotein-defi cient serum (NCLPDS) ( d > 1.215 g/ml) was prepared by ultracentrifugation ( 38 ) .
Antibodies
rabbit anti-serum 3143 against the C-terminal 14 amino acids of the LDLR was the kind gift of J. Herz (University of Texas PCSK9-D347Y (5 µg/ml), and Alexa647-labeled transferrin (100 µg/ml) for 1 h in Medium A. The labeled proteins were chased for 2 h in label-free Medium A containing E64, then visualized directly. Images were taken on an Olympus FV1000 scanning confocal microscope. Colocalization was quantifi ed using Image J (http://rsb.info.nih.gov/ij/).
Endocytic recycling assay
SV589 cells seeded in 24-well plates were cultured overnight in Medium C containing 150 M E64. PCSK9 labeled with thiolcleavable biotin was incubated with IRDye800CW-labeled streptavidin for 1 h at 37°C, and the complexes were then added to the cells. After 1 h, the cells were incubated with 20 mM Tris(2-carboxyethyl)phosphine (TCEP) in buffer B (PBS, 0.1 mM CaCl 2 , 2 mM MgCl 2 , 0.5% BSA (w/v)) for 20 min at 4°C, then washed twice for 10 min with 5 mg/ml iodoacetamide in buffer B. The cells were washed again with buffer B and PBS-CM (PBS, 0.1 mM CaCl 2 , 2 mM MgCl 2 ), then incubated in Medium A, supplemented with TCEP and E64, for 6 h at 37°C. The plate was directly scanned on the LI-COR Odyssey infrared system at time intervals. Signal intensity was quantifi ed using Odyssey 2.0 software, background fl uorescence of untreated wells was subtracted, and signal normalized to DNA levels stained by DRAQ5 emitting at a separate wavelength (Cedarlane Laboratories, Canada) (1:10,000).
Ligand blotting
HEK293 cells cultured in Medium B were transiently transfected with pLDLR17 vector using Lipofectamine 2000 (Life Technologies). After 48 h cells were scraped and pelleted in cold PBS then resuspended on ice in sorbitol microsome buffer (50 mm HEPES-KOH, pH 7.2, 250 mm sorbitol, 10 mm KCl, 1.5 mm MgCl 2 , Complete TM protease inhibitor mixture, 1 mm PMSF) and disrupted with 10 passages through a 23-gauge needle. Membranes were pelleted by centrifugation at 100,000 × g for 30 min then resuspended in pH 6/Triton X-100 buffer (40 mm Tris-maleate, pH 6.0, 100 mm NaCl, 2 mm CaCl 2 , 1 mm MgCl 2 , 1% Triton X-100, Complete TM protease inhibitor mixture, 1 mm PMSF). Membrane proteins (35 g/lane) were resolved on 8% SDS-PAGE in nonreducing loading buffer (50 mM Tris-maleate, pH 6.0, 2 mM CaCl 2 , 0.5% SDS, 10% glycerol, 0.05% bromophenol blue) and transferred to nitrocellulose membranes. Membranes was cut in strips and blocked for 30 min in blocking buffer (50 mm Tris-Cl, pH 7.0, 90 mm NaCl, 2 mm CaCl 2 , 5% (w/v) skim milk), then incubated in blocking buffer with 125 I labeled wild-type PCSK9-FLAG (10 µg/ml) or PCSK9-D374Y (2 µg/ml) in the absence or presence of 50 µg/ml of unlabeled PCSK9-D374Y. Membranes were washed three times in blocking buffer and visualized on a Storm 860 Molecular Imager (GE Healthcare).
Statistical analysis
All presented values are mean and standard deviation. Statistical analysis was determined by Student t -test with GraphPad Prism 5 software.
RESULTS
Limited degradation of LDLRs in SV-589 fi broblasts in response to high PCSK9 concentrations
PCSK9 concentrations in human plasma range from 0.05 to 3 g/ml among healthy individuals ( 40 ) . A recent biotinylated prior to harvesting using EZ-Link Sulfo-NHS-SS-Biotin (Thermo Scientifi c Pierce) as described ( 5 ) . Three quarters of each cell lysate were brought up to 0.5 ml in Tris lysis buffer and rotated overnight at 4°C with streptavidin magnetic beads. The beads were washed three times with Tris-lysis buffer and protein eluted in 1× SDS loading buffer (50 mM Tris-HCl, pH 6.8; 1% SDS; 5% glycerol; 10 mM EDTA; 0.0032% bromophenol blue). Precipitated cell surface protein and whole-cell extract proteins were subjected to 8% SDS-PAGE, transferred to nitrocellulose membrane (Bio-Rad) and incubated with primary antibodies. Infrared dye (IRDye-800)-labeled secondary antibodies were used for detection on LI-COR Odyssey infrared system (LI-COR Biosciences). Band intensity was analyzed using Odyssey 2.0 software.
Flow cytometry
SV-589 and HepG2 cells were cultured overnight in steroldepleting Medium C , respectively, containing 150 µM E64, a noncell-permeable version of a cysteine protease inhibitor shown to inhibit lysosomal degradation of internalized PCSK9 in cultured cells ( 35 ) . Following 1 h incubation with Alexa488labeled PCSK9-D374Y (1 g/ml), cells were washed with stripping buffer (100 mM Na 2-mercapto-ethanesulfonate; 50 mM Tris, pH 8.6; 100 mM NaCl; 1 mM EDTA; 0.2% BSA) to remove cell surface-associated fl uorescence. Harvested cells were fi ltered through a 70 M cell strainer (BD Biosciences) and subjected to fl ow cytometry using a BD FACSAria fl ow cytometer and cell sorter (BD Biosicences). The lower threshold of positive staining was determined using cells not incubated with fl uorescent protein.
125
I-PCSK9 degradation assay
SV-589 and HepG2 cells were cultured overnight in steroldepleting Medium C, respectively, prior to pulse-labeling with 125 I-labeled wild-type PCSK9 (5 µg/ml), PCSK9-D374Y (0.5 µg/ ml), or C7 antibody (0.5 µg/ml) for 1 h in Medium A containing 5% NCLPDS. In control experiments, cells were pretreated for 30 min and then throughout with 50 µM chloroquine to inhibit lysosomal degradation. Following labeling, cells were washed and incubated in label-free Medium A with 5% NCLPDS for 6 h at 37°C. Medium was collected and total protein was precipitated on ice with 10% (v/v) trichloroacetic acid (TCA), and pelleted by centrifugation. TCA-soluble supernatant (1 ml) was removed to glass tubes, and mixed with 10 l of 40% KI followed by 40 l of 30% hydrogen peroxide. Reactions were allowed to stand for 10 min then extracted with 2 ml of chloroform to remove free iodide. A 700 l of the upper aqueous phase containing 125 I-monoiodotyrosine was removed for ␥ counting using a Cobra TM II Auto-Gamma counter. Measurements were normalized to cell protein levels determined by BCA assay .
Live cell imaging and colocalization
SV-589 cells were cultured on Lab-Tek (Nunc) 8-well chambered coverglass and incubated overnight in sterol-depleting Medium C containing 150 M E64. For colocalization of Alexa488-labeled PCSK9 with LysoTracker Red DND-99 (Life Technologies) cells were labeled with Alexa488-labeled wild-type PCSK9 (30 µg/ml) or D347Y PCSK9 (5 µg/ml) for 1 h and chased for up to 6 h in label-free Medium C containing E64. LysoTracker Red DND-99 was incubated at a concentration 200 nM for 2 h prior to the end of each chase period. For colocalization studies of Alexa488-labeled PCSK9 and Alexa647-labeled transferrin, cells were preincubated for a minimum 1 h in serum-free Medium A to deplete endogenous transferrin. Cells were then incubated with Alexa488-labeled wild-type PCSK9 (30 µg/ml) or mRNA and protein expression or medium supplemented with sterols (cholesterol and 25-hydroxycholesterol) to suppress LDLR expression. Cells were then incubated with FLAG-tagged wild-type PCSK9 (5 µg/ml) or PCSK9-D374Y (0.5 µg/ml) for 2 h to allow cell-association and uptake. Wildtype PCSK9 and PCSK9-D374Y were detected in blots of whole cell extracts derived from cells cultured under LDLRinducing conditions whereas cell-associated PCSK9 was decreased to almost undetectable levels for cells cultured with sterols, mirroring the suppression of LDLR protein levels ( Fig. 2A ). To further quantify this effect, we also performed FACS analysis to assess sterol-dependent cell-association and uptake of Alexa488-labeled PCSK9-D374Y in SV-589 fi broblasts as well as HepG2 cells. Cell-associated fl uorescence was decreased over 90% for both cell-lines cultured in the presence of sterols ( Fig. 2B ).
Wild-type PCSK9 and mutant PCSK9-D374Y traffi c to lysosomes in SV-589 fi broblasts
To examine the fate of PCSK9 in SV-589 fi broblasts, we measured lysosomal degradation of internalized 125 I-labeled study showed that SV-589 cells, a line of SV40-transformed human skin fi broblasts, showed no decrease in LDLR levels in response to a 4 h treatment with 10 g/ml concentration of purifi ed PCSK9, whereas this same treatment decreased LDLR levels in HuH7 hepatoma cells and primary human fi broblasts ( 35 ) . To further assess the extent of PCSK9 resistance in SV-589 fi broblasts, we incubated cells with purifi ed recombinant wild-type PCSK9 at high nonphysiological concentrations (5-20 µg/ml) or with a lower concentration (2 µg/ml) of a gain-of-function PCSK9 variant (PCSK9-D374Y) that has increased LDLR affi nity. As a comparison, HepG2 hepatoma cells were treated under identical conditions. Cells were fi rst cultured for more than 16 h in lipoprotein-defi cient medium containing a statin (pravastatin) to induce LDLR mRNA and protein expression. This culture condition also induced endogenous PCSK9 expression and secretion in both cell-lines (data not shown). To eliminate possible interference by secreted endogenous PCSK9, culture medium was replaced immediately prior to 6 h incubation with FLAG-tagged wild-type PCSK9 or PCSK9-D374Y. Cells were harvested and immunoblot analysis was performed to determine PCSK9 and LDLR levels present in whole cell extracts and among cell surface proteins isolated following cell surface biotinylation. As expected, treatment with PCSK9 greatly reduced cell surface LDLR expression in HepG2 hepatoma cells, whereas SV-589 cells remained highly resistant to LDLR degradation, despite similar levels of cell-association of FLAG-tagged PCSK9 ( Fig. 1A ) . While there was a trend toward dose-dependent reduction of SV-589 cell surface LDLR in response to high concentrations of wild-type PCSK9, this effect only reached statistical signifi cance at the highest PCSK9 concentration tested (20 µg/ml), which reduced cell surface LDLR levels by approximately 25% ( Fig. 1B ) . We obtained similar results following longer 18 h incubations with PCSK9 (data not shown), ruling out the possibility that resistance to PCSK9-mediated LDLR degradation observed in SV-589 fi broblasts was due to slower rates of cell surface LDLR endocytosis compared with HepG2 cells. Gain-of-function PCSK9-D374Y at a concentration of 2 µg/ml signifi cantly reduced LDLR levels on the cell surface (>50%) in SV-589 fi broblasts ( Fig. 1B ) , although this response was still much weaker than that seen in HepG2 cells. Thus, immortalized SV589 fi broblasts do not display absolute resistance to PCSK9-mediated LDLR degradation and are susceptible to moderately elevated concentrations of the gain-of-function mutant PCSK9-D374Y.
Sterol-dependent uptake of PCSK9 in SV-589 fi broblasts
High cellular levels of sterols specifi cally suppress transcription of genes containing sterol-regulatory elements within their promoter regions , including LDLR , due to decreased proteolytic processing of the SREBP-2 transcription factor to its active form ( 1 ) . Therefore, to assess whether PCSK9 cell-association and uptake was mediated by the LDLR in SV-589 fi broblasts we cultured SV-589 cells for more than 16 h in either sterol-depleting conditions (lipoproteindefi cient medium containing pravastatin) to induce LDLR Excreted 125 I-monoiodotyrosine (TCA-soluble), a catabolic product of lysosomal degradation of 125 I-labeled proteins ( 38 ) , was then measured in the culture medium as a determinant of lysosomal traffi cking and degradation of internalized radioiodinated PCSK9. These values were corrected for nonlysosomal degradation, measured as TCA-soluble radioactivity generated in cells preincubated with 50 µM chloroquine (typically less than 10% of total counts). Internalized 125 I-labeled wild-type PCSK9 was degraded in lysosomes of SV-589 fi broblasts at high levels comparable to that in HepG2 cells ( Fig. 3C ) . Despite a 4-fold lower concentration used for cell labeling, 125 I-PCSK9-D374Y was degraded at 2.6-fold and 1.5-fold higher levels than wild-type PCSK9 in HepG2 cells and SV-589 fi broblasts, respectively. Thus, the effi ciency of PCSK9-D374Y degradation was approximately 10-fold higher than wild-type PCSK9 in HepG2 cells compared with approximately 6-fold in SV-589 cells ( Fig. 3D ) . HepG2 cells and SV-589 fi broblasts internalized and degraded equivalent amounts of 125 I-labeled C7 monoclonal antibody, which releases from the LDLR within the acidic environment of early endosomes ( 41 ) , indicating that cell surface LDLR expression and receptor endocytosis were comparable between the two cell-lines (data not shown).
To further confi rm lysosomal traffi cking of PCSK9 proteins in SV-589 fi broblasts, we performed live-cell confocal microscopy analysis to assess colocalization of internalized Alexa488-labeled wild-type PCSK9 and PCSK9-D374Y with LysoTracker, a cell-stain specifi c for acidic late endosomes/ lysosomes. Cells were fi rst pulse-labeled with fl uorescentlylabeled PCSK9 proteins for 1 h in medium containing E64, an inhibitor of lysosomal cysteine proteases, then washed to remove unbound label and incubated for a further 6 h in the presence of E64. Internalized Alexa488-labeled PCSK9 was initially localized in diffuse punctate structures throughout the cytoplasm that over a 6 h time-period showed increased colocalization with LysoTracker ( Fig. 4 ), indicating the traffi cking of both wild-type PCSK9 and PCSK9-D374Y to lysosomes.
Internalized mutant PCSK9-D374Y, but not wild-type PCSK9, enters a recycling pathway in SV-589 fi broblasts
Relative to the degradation of wild-type PCSK9, the degradation of 125 I-labeled PCSK9-D374Y appeared to be less effi cient in SV-589 fi broblasts compared with HepG2 cells ( Fig. 3D ), suggesting that a lower proportion of internalized PCSK9-D374Y traffi cs to lysosomes in fi broblasts. To assess potential cell surface recycling of this LDLR ligand in SV-589 fi broblasts, we performed live-cell confocal microscopy analysis to determine colocalization of internalized Alexa488-labeled PCSK9-D374Y with Alexa647-labeled transferrin (Tf), a marker of the endocytic recycling compartment (ERC). Cells were pulsed with fl uorophore-labeled PCSK9-D374Y and Tf for 1 h, followed by a 4 h chase period to allow movement out of early endosomal compartments. Following this treatment, PCSK9-D374Y was robustly colocalized with Tf in punctate cytoplasmic structures, indicating that a substantial proportion of internalized PCSK9-D374Y traffi cked to the ERC in SV-589 fi broblasts ( Fig. 5A , C ) . In contrast, there was minimal ERC localization of internalized wild-type PCSK9 and PCSK9-D374Y. For comparison purposes, we performed the same experiments in HepG2 cells, which have previously been shown to degrade 125 I-labeled PCSK9 within lysosomes ( 28 ) . Radioiodinated PCSK9 consisted of intact prodomain and catalytic/C-terminal domain segments ( Fig. 3A ) and showed a high specifi city for binding to LDLRs, as demonstrated by ligand blotting of total membrane protein extracts from HEK293 cells transiently overexpressing LDLR ( Fig. 3B ). As expected, 125 I-labeled PCSK9-D374Y displayed increased binding affinity for LDLRs compared with wild-type PCSK9 ( Fig. 3B ) . For cellular degradation studies, SV-589 and HepG2 cells were pulselabeled for 1 h with 125 I-labeled wild-type PCSK9 (2 µg/ml) or PCSK9-D374Y (0.5 µg/ml) followed by a 6 h chase period. A: SV-589 fi broblasts were cultured for more than 16 h in the absence ( Ϫ ) or presence (+) of sterols as described in Materials and Methods prior to 2 h treatment with purifi ed FLAG-tagged wildtype PCSK9 (5 µg/ml) or PCSK9-D374Y (0.5 µg/ml). Whole-cell protein extracts were subjected to 8% SDS-PAGE and immunoblot detection of LDLR and the FLAG epitope on PCSK9. Mature LDLR as well as a precursor form (pLDLR) were detected (arrows). TfR was detected as a control for loading. Secondary IRDye800-labeled antibodies were used and blots were imaged on a LI-COR Odyssey infrared system. B: SV-589 and HepG2 cells were cultured as in (A) in the continuous presence of E64 (150 M) to inhibit endolysosomal cysteine protease activity. Cells were incubated for 1 h with Alexa488-labeled PCSK9-D374Y (1 g/ml) and collected for FACS analysis as described in Materials and Methods. A lower threshold for positive staining was determined based on cells not incubated with fl uorescent PCSK9. Results shown represent the mean and standard deviation from three separate experiments. fl uorescent PCSK9-S-S-biotin-800streptavidin complexes. To remove surface fl uorescence, cells were washed in a buffer containing the reducing agent TCEP, which is highly charged and does not cross cell membranes ( 42 ) . Labeled cells were then cultured in medium containing TCEP to cleave the releasable fl uorescent tag from PCSK9 complexes returning to the cell surface, and time-dependent loss of cell-associated fl uorescence was quantifi ed as a measure of endocytic recycling ( Fig. 6A ). Culture medium Alexa488-labeled wild-type PCSK9 under the same conditions ( Fig. 5B, C ) , consistent with predominant traffi cking of wild-type PCSK9 to lysosomes.
To quantify the amount of cell surface recycling of wildtype PCSK9 and PCSK9-D374Y in SV-589 fi broblasts, we turned to a recycling assay using PCSK9 covalently modifi ed with thiol-cleavable biotin (S-S-biotin). Biotinylated PCSK9 was labeled in solution with IRDye800-labeled streptavidin and added to cells for 1 h to allow uptake of . 4 . Wild-type PCSK9 and PCSK9-D374Y traffi c to lysosomes in SV-589 fi broblasts. SV-589 cells seeded on 8-well chambered coverglass were cultured for more than 16 h in sterol-depleting Medium C in the presence of E64 (150 M). Cells were labeled with Alexa488-labeled wild-type PCSK9 (30 g/ml) or PCSK9-D347Y (5 µg/ml) for 1 h and chased up to 6 h in label-free Medium C containing E64. LysoTracker Red DND-99 was incubated at concentration 200 nM for 2 h prior the end of the chase period. Images were taken on Olympus FV1000 scanning confocal microscope. The percentage of colocalization of PCSK9 fl uorescence with the lysosomal marker LysoTracker was quantifi ed using Image J software from fi ve or more fi elds encompassing more than 100 cells for each condition. Results shown are the mean and standard deviation from three separate experiments. also contained E64 to prevent potential loss of cell-associated fl uorescence due to lysosomal degradation. Following a 6 h period, greater than 50% of internalized PCSK9-D374Y complexes recycled to the cell surface versus less than 10% for wild-type PCSK9 ( Fig. 6B ) , further demonstrating the differential traffi cking of wild-type PCSK9 and PCSK9-D374Y in SV-589 fi broblasts. Under identical assay conditions, there was less than 10% loss of fl uorescence for internalized wild-type PCSK9 or PCSK9-D374Y in HepG2 cells ( Fig. 6C ) , consistent with predominant traffi cking of PCSK9 to lysosomes in hepatic cells.
DISCUSSION
The degree of LDLR degradation in response to exogenous PCSK9 varies among cell-types in culture. PCSK9 efficiently targets the LDLR for lysosomal degradation in liver-derived cells but not immortalized fi broblast celllines, despite LDLR-dependent uptake into endolysosomal compartments ( 5, 35 ) . It is unknown whether internalized PCSK9 remains associated with LDLR in resistant cell-types, or if it dissociates within early endosomes prior to LDLR recycling. In the current study, we report that PCSK9 is released from the LDLR and delivered to lysosomes as a dissociated ligand in SV-589 cells, a line of SV40-transformed Fig. 5 . Traffi cking of PCSK9-D374Y to endocytic recycling compartments in SV-589 cells. SV-589 cells seeded on 8-well chambered coverglass were cultured for more than 16 h in sterol-depleting Medium C in the presence of E64 (150 M). Cells were labeled with 5 µg/ml AlexaFluor 488-labeled PCSK9-D374Y (A) or 30 µg/ml wild-type PCSK9 (B) along with 100 µg/ml Alexa647-labeled transferrin for 1 h in Medium A. Labeling medium was replaced with label-free Medium A containing E64 for a 2 h chase period and images were taken on Olympus FV1000 scanning confocal microscope. C: The percentage of colocalization of PCSK9 fl uorescence with that of the endocytic recycling compartment marker transferrin was quantifi ed using Image J software from fi ve or more fi elds encompassing more than 100 cells for each condition. Results shown are the mean and standard deviation from three separate experiments.
Fig. 6.
A large proportion of internalized PCSK9-D374Y recycles to the cell surface in SV-589 fi broblasts. A: SV-589 cells seeded on 24-well plates were cultured for more than 16 h in steroldepleting Medium C in the presence of E64 (150 M). Wild-type PCSK9 or PCSK9-D347Y covalently modifi ed with thiol-cleavable (S-S)-biotin was preincubated with IRDye800CW streptavidin in Medium A for 1 h and added to cells for 1 h at 37°C. Labeling medium was replaced with label-free Medium A containing the noncell-permeable reducing agent TCEP (20 mM) and E64 (150 M) and incubated at 37°C for a 6 h chase period. Plates were scanned directly on a LI-COR Odyssey infrared system at the indicated time points to measure remaining cell-associated fl uorescence. Individual wells from a representative experiment are shown. B: Quantifi cation of PCSK9-S-S-biotin-800Streptavidin recycling based on total fl uorescence following continuous exposure to TCEP. Values were normalized to cell density measured using a DNA stain (DRAQ5). Results shown are expressed relative to the start of the 6 h chase period and represent the mean and standard deviation of three separate experiments. C: Lack of cell surface recycling of internalized PCSK9-D374Y in HepG2 cells. HepG2 cells were cultured and treated as in (A). Plates were scanned directly on a LI-COR Odyssey infrared system at the indicated time points to measure remaining cell-associated PCSK9 fl uorescence. Individual wells are shown from a representative experiment repeated two other times with similar results.
In the current study, we found that lysosomal degradation of 125 I-labeled PCSK9-D374Y was 2.6-fold higher than wild-type PCSK9 in HepG2 cells despite being added to culture medium at a 4-fold lower concentration ( Fig. 3C ) . Thus, the effi ciency of PCSK9-D374Y degradation was approximately 10-fold higher than wild-type PCSK9, in accordance with a 10-to 25-fold increased binding affi nity to the LDLR at physiological pH. PCSK9-D374Y treatment (2 µg/ml) reduced cell surface LDLRs in SV-589 cells by approximately 50% ( Fig. 1B ) , indicating that this gainof-function mutant PCSK9 was able to direct LDLR degradation, albeit at lower levels than in HepG2 cells. Decreased LDLR degradation activity by PCSK9-D374Y in SV-589 fi broblasts could be due to ineffi cient lysosomal targeting of LDLRs by bound PCSK9. Indeed, internalized PCSK9-D374Y was shown to traffi c to either lysosomes ( Fig. 4 ) or to transferrin-positive endocytic recycling compartments in SV-589 fi broblasts ( Fig. 5 ). We did not observe localization of fl uorophore-labeled PCSK9-D374Y in endocytic recycling compartments of HepG2 cells (data not shown).
One potential mechanism for LDLR degradation mediated by PCSK9 is through interference with a closed conformation of the LDLR in acidic endocytic compartments (28) (29) (30) . LDLR mutations that negatively affect the closed conformation lead to defective LDLR recycling and increased degradation in cultured cells (50) (51) (52) . Surprisingly, a large proportion (>50%) of internalized PCSK9-D374Y recycled to the cell surface in SV-589 fi broblasts, presumably still bound to the LDLR ( Fig. 6B ). This suggests that bound PCSK9 does not greatly affect the open-to-closed conformational switch in SV-589 cells or that other factors are required for effi cient degradation of LDLR. In fi broblasts, endocytosis of LDLR in clathrin-coated vesicles is predominantly mediated by the adaptor protein Disabled-2 ( 53 ), whereas ARH is required for endocytosis of LDLR in hepatic cells ( 54 ) . ARH was shown to be essential for PCSK9mediated LDLR degradation in primary mouse hepatocytes ( 5 ) but not in primary human fi broblasts ( 35 ) . There is evidence that membrane receptors and their ligands can be sorted into clathrin-coated vesicles that merge with distinct subpopulations of early endosomes depending on the adaptor proteins involved ( 55, 56 ) . The divergence of pathways for PCSK9-D374Y bound to LDLR in SV-589 fi broblasts (lysosomal versus recycling) may refl ect less stringent adaptor-mediated sorting in fi broblasts compared with hepatocytes.
Importantly, we found that internalized 125 I-labeled wild-type PCSK9 was degraded in lysosomes at comparable levels in HepG2 cells and SV-589 fi broblasts ( Fig. 3C ). Since cell surface LDLR levels were minimally decreased in SV-589 cells in response to PCSK9 ( Fig. 1 ) , this indicates that the majority of internalized PCSK9 was released from the LDLR, which was then free to recycle to the cell surface. In further support of this conclusion, we demonstrated that wild-type PCSK9 traffi cked to lysosomes in SV-589 fi broblasts ( Fig. 4 ) and did not recycle to the cell surface ( Fig. 6A, B ) . The fi nding that PCSK9 releases from LDLRs in acidic early endosomes of certain cell-types was human skin fi broblasts with a robust PCSK9-resistant phenotype. A gain-of-function D374Y mutant PCSK9 with increased binding affi nity to LDLR was capable of directing LDLR degradation in a limited manner in these cells; however, much of the internalized PCSK9-D374Y was recycled to the cell surface, presumably still bound to the LDLR. We conclude that two factors diminish PCSK9 activity in SV-589 fi broblasts: i ) an increased dissociation from the LDLR in early endosomes, and ii ) a decreased ability of bound PCSK9 to inhibit LDLR recycling.
Tissue specifi city to circulating PCSK9 has been observed in mice, with PCSK9 activity toward LDLRs being suppressed in extrahepatic tissues such as adrenal gland and kidney ( 27, 43, 44 ) . Compared with liver, there was decreased accumulation of injected 125 I-labeled PCSK9 in adrenal gland in a recent study ( 45 ) , suggesting that PCSK9 uptake was inhibited in this tissue, perhaps due to a blocking effect on LDLR binding exerted by extracellular annexin A2 ( 44, 46 ) . In contrast, cell-association and uptake of exogenous wild-type PCSK9 and gain-of-function PCSK9-D374Y was normal in PCSK9-resistant SV-589 fi broblasts ( Fig. 1 ) , thus implicating an intracellular mechanism of PCSK9 inhibition. In SV-589 cells treated with sterols to suppress LDLR mRNA and protein expression, the uptake of PCSK9 was reduced to almost undetectable levels ( Fig. 2 ) . This is in agreement with a previous report in which an unambiguous role of the LDLR for PCSK9 internalization was determined through the use of MEF cells derived from wild-type or Ldlr Ϫ / Ϫ mice ( 5 ) . Missense mutations in PCSK9 (D374Y) or LDLR (H306Y) that improve specifi c bond interactions at the PCSK9-LDLR interface increased cellular uptake of PCSK9 accordingly ( 5, 19 ) . Injection studies in mice demonstrated that the plasma clearance rate of gain-of-function PCSK9-D374Y was increased compared with that of wild-type PCSK9, supporting a direct role of LDLR in PCSK9 uptake in vivo ( 27 ) . A recent report suggests that PCSK9 degradation in hepatic cells is directly mediated by an interaction with amyloid precursor-like protein 2 (APLP2), a ubiquitously expressed cell surface protein known to be involved in lysosomal traffi cking of MHC class I K d molecules ( 47 ) . In this model, constitutive lysosomal traffi cking of PCSK9 is mediated by APLP2, and LDLR is degraded as a consequence of binding to PCSK9; LDLR-dependence of PCSK9 uptake is explained by an unappreciated role of the LDLR in the organization of endocytic adaptor proteins and receptor clustering at the plasma membrane. However, it should be noted that LDLR is dispersed on the plasma membrane in hepatocytes but clustered in coated pits in fi broblasts ( 48 ) . The viability of Ldlr Ϫ / Ϫ mice also argues against a general role of the LDLR in adaptor protein recruitment and receptor clustering in coated pits. PCSK9 association with APLP2 requires the C-terminal domain of PCSK9 ( 47 ) and could explain antigen-mediated clearance of therapeutic blocking antibodies targeting the PCSK9 catalytic domain ( 49 ) . However, this pathway may not represent a predominant means of PCSK9 internalization in cells and tissues when LDLR binding is not inhibited. unanticipated since in vitro studies have shown that the binding affi nity of PCSK9 to LDLR is greatly enhanced (>100-fold) at acidic pH (<5.5) as compared with physiological pH 7.4 ( 12, 13 ) . However, a study of 125 I-labeled PCSK9 binding to LDLR showed that the most pronounced increase occurred over a pH range (6.0-5.2) typical of late endosomal compartments ( 9 ) . Therefore the pH effect could be more modest in early endosomes that are mildly acidic (5.9-6.8) and perhaps outweighed by other factors that promote PCSK9 dissociation from LDLR.
The LDLR EGF-A domain contains a noncanonical Ca 2+ binding site ( 57 ) and Ca 2+ coordination is required for PCSK9 association ( 9 ) . Interestingly, the K D for the Ca 2+ binding in the EGF-A domain was determined to be approximately 50 µM, leading to the suggestion that the EGF-A Ca 2+ site may be titrated in the low Ca 2+ environment of early endosomes ( ‫ف‬ 10-50 µM) ( 57 ) . This could in turn trigger PCSK9 dissociation dependent on other factors such as pH and PCSK9 mutations that affect LDLR binding affi nity. It is possible the pH and Ca 2+ environment in early endosomes of hepatocytes strongly favors persistent PCSK9 binding to LDLR, whereas alterations in these parameters (higher pH and/or lower Ca 2+ ) favor PCSK9 dissociation in resistant cells. The luminal ionic composition in the endolysosomal compartment can vary in an incremental manner between cell-types, largely dependent on differential expression of membrane ion pumps and channels ( 58, 59 ) . This could dictate a range of potencies for PCSK9-mediated LDLR degradation across various cell-types and tissues, with hepatocytes and immortalized fi broblasts representing different ends of the spectrum. Dissociation of wild-type PCSK9 from the LDLR in early endosomes of SV-589 fi broblasts was likely not absolute, as high concentrations (20 µg/ml) signifi cantly lowered cell surface LDLRs by approximately 25% ( Fig. 1B ) .
For PCSK9 to direct LDLR traffi cking it must remain bound to the receptor in early endosomes, a major site for the sorting of membrane components destined for recycling to the cell surface from those targeted for degradation in lysosomes. Our fi ndings identify dissociation from the LDLR in early endosomal compartments as a determining mechanism for cell-type-specifi c resistance to PCSK9, a protein of major clinical importance for its ability to mediate LDLR degradation in liver. Continued study of the mechanisms regulating PCSK9 release from recycling LDLRs in PCSK9-resistant fi broblasts could shed light on factors that promote persistent binding in hepatocytes, eventually leading to LDLR degradation.
